FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025.
Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2025 Earnings Conference August 12, 2025 10:00 AM ET Company Participants Irina Kuznetsova - Corporate Participant Jonathan Baksh - Executive VP & CFO Rahim Suleman - CEO, President & Director Conference Call Participants Ian Brooks Gillies - Stifel Nicolaus Canada Inc., Research Division J. Marvin Wolff - Paradigm Capital Inc., Research Division ...
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.